New Standard of Care in Locally Advanced Head and Neck Cancer
(MedPage Today) — Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) prolonged event-free survival (EFS), the randomized KEYNOTE-689 trial…
